Monograph

J07BD52 - Measles, Combinations with Mumps and Rubella, Live Attenuated

Propably not porphyrinogenic

Important Information

In general, vaccines are regarded safe since such substance is not suspected to give an up-regulation of the heme biosynthesis as a direct effect. However, some vaccines can cause a reaction with high fever persisting over days as a side effect. It is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to. Vigilance is therefore motivated when administrating a vaccine known to cause reactions with fever.

Side effects

Fever is reported as a very common side effect the combined measles, mumps and rubella vaccine, and it is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to.

Rationale

Based on the pharmacokinetics of the measles, combinations with mumps and rubella vaccine, there are no conceivable porphyrinogenic effects.

Chemical description

Live, attenuated measles, mumps and rubella viruses.

Therapeutic characteristics

The measles, combinations with mumps and rubella vaccine is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals from 12 months of age. It is administered by intramuscular injection.

Metabolism and pharmacokinetics

The measles, combinations with mumps and rubella vaccine is not metabolized by the Cytochrome P450 system.

References

#	Citation details	PMID
*	Government bodies
1.	Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
*	Summary of Product Characteristics
2.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). M-M-RVAXPRO. (Last edition: 20.11. 2014).

Citation details

PMID

Government bodies

Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). M-M-RVAXPRO. (Last edition: 20.11. 2014).

Similar drugs

Explore alternative drugs in similar therapeutic classes J07B / J07BD or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

M-M-RVAXPRO · M-M-RVAXPRO, poeder en oplosmiddel voor suspensie voor injectie · M-M-RVAXPRO voor · M-M-RVAXPRO poeder en oplosmiddel voor suspensie voor injectie in een voorgevulde injectiespuit · Priorix · Priorix, poeder en oplosmiddel voor oplossing voor injectie

Belgium

M-M-RVaxPro s.c./i.m. · M-M-RVaxPro susp. inj. (pdr. + solv.) s.c./i.m. flac. · M-M-RVaxPro susp. inj. (pdr. + solv.) s.c./i.m. ser. préremplie flac. · Priorix s.c./i.m. · Priorix sol. inj. (pdr. + solv.) s.c./i.m. amp. ser. préremplie flac.

United Kingdom

M-M-R II vaccine · M-M-R II vaccine powder and solvent for solution for injection 0.5ml vials · M-M-RVAXPRO vaccine · M-M-RVAXPRO vaccine powder and solvent for suspension for injection 0.5ml pre-filled syringes · Priorix vaccine · Priorix vaccine powder and solvent for solution for injection 0.5ml pre-filled syringes · Priorix vaccine powder and solvent for solution for injection 0.5ml vials

Denmark